The Haematological Malignancy Diagnostic Service based at Leeds General Infirmary has made significant improvements to its leukaemia diagnosis and classification service
The Haematological Malignancy Diagnostic Service based at Leeds General Infirmary has made significant improvements to its leukaemia diagnosis and classification service thanks to a new method using BD Oncomark reagents from BD Biosciences.
The Leeds department is an amalgamation of laboratories offering a centralised and highly specialised diagnostic service for leukaemias and lymphomas.
Steve Richards, consultant clinical scientist in the department, explained: "BD Oncomark reagents are a range of high quality labelled monoclonal antibodies which, when used in specific combinations, allow us to diagnose the various types of leukaemia, look at the prevalence of normal cells, and even to identify different populations of leukaemic cells.
Our results are far better than before and the overall improvement in service has been particularly significant for our Acute Myeloid Leukaemia (AML) patients.
We can now get detailed information on AML patients in just two hours, information that is critical for deciding on the aggressive treatment programme that patient should undergo."
